Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0033) is a clinical research site located in New Brunswick, New Jersey, United States 08903.

Crixeo Health Trust Score: 62/100 (FAIR). This profile has not yet been claimed by the site owner.

Rutgers Cancer Institute of New Jersey ( Site 0033) has participated in 4 clinical trials with 4 currently active.

Therapeutic areas: Breast Neoplasms, Prostate Cancer Metastatic, Metastatic Castration-resistant Prostate Cancer (mCRPC).

Sponsors: Merck Sharp & Dohme LLC.

Sponsor Feasibility Report

Trust Score: 62/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Rutgers Cancer Institute of New Jersey ( Site 0033)?

Rutgers Cancer Institute of New Jersey ( Site 0033) has a Crixeo Trust Score of 62/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Rutgers Cancer Institute of New Jersey ( Site 0033) conducted?

Rutgers Cancer Institute of New Jersey ( Site 0033) has 4 clinical trials on record, with 4 currently active. Their work covers Breast Neoplasms, Prostate Cancer Metastatic, Metastatic Castration-resistant Prostate Cancer (mCRPC).

Is Rutgers Cancer Institute of New Jersey ( Site 0033) accredited by Crixeo Health?

Rutgers Cancer Institute of New Jersey ( Site 0033) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Rutgers Cancer Institute of New Jersey ( Site 0033)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.